

2 - 2

5.1.1c

5.1.1c

From: 5.1.2e) <5.1.2e @minvws.nl>

Sent: 29 June 2020 1:25 PM

To: 5.1.2e <5.1.2e @5.1.2e.com>

Cc: 5.1.2e) <5.1.2e @minvws.nl>

Subject: FW: Vaccines - follow-up

Dag 5.1.2e

Zou jij bijgevoegd contract met Sanofi willen bekijken?

Voornamelijk het liability-stuk is voor ons op dit moment interessant, andere delen kunnen we op een later moment bekijken.

5.1.2e belt je over een kwartier.

Groet,

5.1.2e

Van: 5.1.2e) <5.1.2e @minvws.nl>

Verzonden: maandag 29 juni 2020 10:57

Aan: 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl;

Onderwerp: FW: Vaccines - follow-up

Van: 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>

Datum: maandag 29 jun. 2020 10:13 AM

Aan: 5.1.2e @gov.se <5.1.2e @gov.se>, 5.1.2e @bmg.bund.de <5.1.2e @bmg.bund.de>, 5.1.2e @minvws.nl, 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>, 5.1.2e @aemps.es <5.1.2e @aemps.es>, 5.1.2e @bmg.bund.de <5.1.2e @bmg.bund.de>, 5.1.2e @sanita.it <5.1.2e @sanita.it>, 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>, 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>, 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>, 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>, 5.1.2e @pm.gouv.fr <5.1.2e @pm.gouv.fr>, 5.1.2e @ec.europa.eu <5.1.2e @ec.europa.eu>

< 5.1.2e @ec.europa.eu>, 5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>, 5.1.2e @pzh.gov.pl < 5.1.2e @pzh.gov.pl>, 5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>, 5.1.2e @gmail.com < 5.1.2e @gmail.com>, 5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>, 5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu>

Onderwerp: FW: Vaccines - follow-up

Dear all,

As per request we have received the info from Sanofi. Please have a look at it and let us discuss this in a mtg.

Best,

5.1.2e

From: 5.1.2e /FR < 5.1.2e @sanofi.com>

Sent: Monday, June 29, 2020 10:01 AM

To: 5.1.2e (TRADE) < 5.1.2e @ec.europa.eu>

Cc: 5.1.2e (COMP) < 5.1.2e @ec.europa.eu>; CARLUCCI 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e @pm.gouv.fr; 5.1.2e /FR < 5.1.2e @sanofi.com>; 5.1.2e /SG < 5.1.2e @sanofi.com>; 5.1.2e @sanofi.com; 5.1.2e (SG) < 5.1.2e @ec.europa.eu>; 5.1.2e (TRADE) < 5.1.2e @ec.europa.eu>; 5.1.2e @gsk.com; 5.1.2e @gsk.com

Subject: Vaccines - follow-up

Dea 5.1.2e

As agreed during our last meeting, please find attached the revised joint Sanofi and GSK proposal including three documents:

- Cover Letter explaining the principles of the revised Term Sheet (version 2)
- Joint Sanofi Pasteur and GSK Term Sheet version 2 with detailed appendices: this version replaces the precedent version
- Answers to your questions list – guiding you in the Term Sheet version 2

We look forward to your feedback, after your meeting with the Steering Board.

In the meantime, should you have any questions, please contact us.

Best regards,

5.1.2e on behalf of Sanofi Pasteur and GSK

This message and any attachments are intended only for use by the named addressee. They may contain confidential or privileged information. If you are not the named recipient of this communication, please contact the sender immediately and delete or destroy the communication without copying it, disclosing its contents to any other person, or using it in any other way.

All services are provided on the basis of an agreement with HOYNG ROKH MONEGIER LLP, a Limited Liability Partnership under the law of England and Wales. The agreement is subject to the General Conditions of HOYNG ROKH MONEGIER LLP of the local office involved. Those General Conditions contain a limitation of liability. A copy of the General Conditions will be forwarded upon request and may also be found at www.hoyngrokhmonegier.com.